Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma

ClinicalTrials.gov ID: NCT01181895

Public ClinicalTrials.gov record NCT01181895. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 24, 2026, 11:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.

Study identification

NCT ID: NCT01181895
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: GlaxoSmithKline; Industry
Enrollment: 348 participants

Conditions and interventions

Conditions

Asthma

Interventions

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 1, 2010 (Type not available)
Primary completion: Aug 1, 2011 (Actual)
Completion: Aug 26, 2011 (Actual)
Last update posted: Nov 8, 2017

2010 – 2011

United States locations

U.S. sites: 11
U.S. states: 8
U.S. cities: 11

Facility	City	State	ZIP	Site status
GSK Investigational Site	Huntington Beach	California	92647	—
GSK Investigational Site	Orlando	Florida	32822	—
GSK Investigational Site	Tallahassee	Florida	32308	—
GSK Investigational Site	Lawrenceville	Georgia	30046	—
GSK Investigational Site	Skillman	New Jersey	08558	—
GSK Investigational Site	Raleigh	North Carolina	27607	—
GSK Investigational Site	Cincinnati	Ohio	45231	—
GSK Investigational Site	Oklahoma City	Oklahoma	73103	—
GSK Investigational Site	Chester	South Carolina	29706	—
GSK Investigational Site	Clinton	South Carolina	29325	—
GSK Investigational Site	Orangeburg	South Carolina	29118	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 23 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01181895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 8, 2017 · Synced Oct 24, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01181895 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →